Increased efficiency of detecting genetically aberrant cells by UroVysion test on voided urine specimens using automated immunophenotypical preselection of uroepithelial cells

Cytometry Part A

Volumn 73, Issue 3, 2008, Pages 259-265

  Pajor, Gabor ^a   Sule, Norbert ^a   Alpar, Donat ^a   Kajtar, Bela ^a   Kneif, Maria ^a   Bollmann, Daniel ^b   Somogyi, Laszlo ^a   Pajor, Laszlo ^a,c  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Institute of Pathology   (Germany)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Cytokeratin 7; Fluorescence in situ hybridization; Transitional cell carcinoma; UroVysion; Voided urine cell specimens

Indexed keywords

CYTOKERATIN 7;

ANTIBODY LABELING; ARTICLE; CANCER STAGING; CHROMOSOME ABERRATION; EPITHELIUM CELL; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MICROSCOPE; MORPHOMETRICS; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINE CYTOLOGY;

CELL LINE, TUMOR; EPITHELIAL CELLS; HUMANS; IMMUNOPHENOTYPING; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 40049100621     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.20528     Document Type: Article

References (25)

1. Leppert JT, Shvarts O, Kawaoka K, Lieberman R, Belldegrun AS, Pantuck AJ. Prevention of bladder cancer: A review. Eur Urol 2006;49:226-234.
2. Dey P. Urinary markers of bladder carcinoma. Clin Chim Acta 2004;340:57-65.
3. Allard P, Bernard P, Fradet Y, Tetu B. The early clinical course of primary Ta and TI bladder cancer: A proposed prognostic index. Br J Urol 1998;81:692-698.
4. Kurth KH, Denis L, Bouffioux C, Sylvester R, Debruyne FM, Pavone-Macaluso M, Oosterlinck W. Factors affecting recurrence and progression in superficial bladder tumors. Eur J Cancer A 1995;31:1840-1846.
5. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, Bono AV, Getzenberg RH, Goebell P, Schmitz-Drager BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Bladder tumor markers beyond cytology: International consensus panel on bladder tumor markers. Urol 2005;66 (6 Suppl 1):35-63.
6. Knowles M. What we could to now: Molecular pathology of bladder cancer. Mol Pathol 2001;54:215-221.
7. Pycha A, Lodde M, Comploj E, Negri G, Egarter-Vigl E, Vittadello F, Susuardi L, Palermo S, Mian C. Intermediate-risk urothelial carcinoma: An unresolved problem? Urol 2004;63:472-475.
8. Brandau S, Boehle A. Bladder cancer. I. Molecular and genetic basis of carcinogenesis. Eur Urol 2001;39:491-497.
9. Oesterlinck W, Jakse G, Malmström P. Guidelines on Bladder Carcinoma, updated version. Arnhem, The Netherlands: European Association of Urology; 2000. pp 8-11.
10. van der Meijden A, Böhle A, Oosterlinck W, Stockle M, Sternberg C. Recommendation form the EAU Working Party on superficial bladder cancer. Eur Urol 2002;41:105-112.
11. Sanches-Carbayo M. Recent advances in bladder cancer diagnostics. Clin Biochem 2004;37:562-571.
12. Wiener HG, Mian CH, Haitel A, Pycha A, Schatzl G, Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998;159:1876-1880.
13. Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, Cheville JC, Sebo TJ, Ramakumar S, Stewart CS, Pankratz S, O'Kane DJ, Seelig SA, Lieber MM, Jenkins RB. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164:1768-1775.
14. Veeramachaneni R, Nordberg ML, Turbat-Herrera EA. Fluorescence in situ hybridization as an ancillary tool in urine cytology to diagnose urothelial carcinoma. Pathol Case Rev 2002;7:70-74.
15. Bassi P, De Marco V, De Lisa A, Mancini M, Pinto F. Non-invasive diagnostic tests for bladder cancer: A review of the literature. Urol Int 2005;75:193-200.
16. Pajor L, Szuhai K, Méhes G, Kosztolanyi G, Jakso P, Lendvai G, Szanyi I, Kajtar P. Combined metaphase, interphase cytogenetic, and flow cytometric analysis of DNA content of pediatric acute lymphoblastic leukaemia. Cytometry 1998;34:87-94.
17. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;2:116-123.
18. Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS, Procop GW, Jones JS, Ulchaker J, Zippe CD, Tubbs RR. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003;169:2101-2105.
19. Junker K, Hartmann A, Tanke HJ, Morrison L, Obermann E, Wiegant J, Van der Burg M, Gamper C, Pelger R, Seelig S, Schubert J. Evaluation of a multi-color fluorescence in situ hybridization assay for the detection of bladder cancer - Results from three European laboratories. J Urol 2002;167 (Suppl):164, A657.
20. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, Zadra J, Burzon D, Osher G, Bridge JA, Anderson S, Johansson SL, Lieber M, Soloway M, Flom K. Clinical evaluation of multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168:1950-1954.
21. DeMay RM. The Art and Science of Cytopathology, Vol. 1: Exfoliative Cytology, 1st ed. Chicago: ASCP Press; 1996. pp 390-393.
22. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24.
23. Schaafsma HE, Ramaekers FCS. Cytokeratin subtyping in normal and neoplastic epithelium: Basic principles and diagnostic applications. Pathol Annu 1994;29:21-62.
24. Daniely M, Rona R, Kaplan T, Olsfanger S, Elboim L, Zilberstein Y, Friberger A, Kidron D, Kaplan E, Lew S, Leibovitch I. Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples. Urolology 2005;66:1354-1359.
25. Bollmann M, Heller H, Bánkfalvi A, Griefingholt H, Bollmann R. Quantitative molecular urinary cytology by fluorescence in situ hybridization: A tool for tailoring surveillance of patients with superficial bladder cancer? BJU Int 2005;95:1219-1225.